Sarepta Therapeutics, Inc. (SRPT) shares collapsed 45.30 percent, or $16.40, to $19.78 on Monday after reports of a possible death of a recipient in the company's second gene therapy clinical trial stated by Investor's Business Daily. The news has sparked significant investor concern over the safety profile of the treatment. The stock opened at $21.26 and has fluctuated between $18.30 and $21.55 during the session on the Nasdaq. Volume has spiked to 25.96 million shares, sharply higher than the average of 3.90 million. The 52-week range for the stock is $18.30 to $173.25.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.